TABLE 2.
Insulin and noninsulin diabetes medication purchases for patients based on data 1 year before index and EOS (year 2019).
| Naïve users | Prevalent users | |||||||
|---|---|---|---|---|---|---|---|---|
| T1D index | T1D 2019 | T2D index | T2D 2019 | T1D index | T1D 2019 | T2D index | T2D 2019 | |
| N | 4016 | 3839 | 47 154 | 38 031 | 30 343 | 27 227 | 63 507 | 37 990 |
| Insulin purchases | ||||||||
| Any insulin purchase (A10A) | ‐ | 3719 (96.9) | ‐ | 35 352 (93) | 30 151 (99.4) | 26 847 (98.6) | 62 259 (98.0) | 35 531 (93.5) |
| Any fast‐acting insulin (A10AB) a | ‐ | 3439 (89.6) | ‐ | 8453 (22.2) | 28 751 (94.8) | 26 116 (95.9) | 22 386 (35.2) | 17 210 (45.3) |
| Degludec | ‐ | 824 (21.5) | ‐ | 2333 (6.1) | 0 (0) | 7062 (25.9) | 0 (0) | 2618 (6.9) |
| Detemir | ‐ | 1007 (26.2) | ‐ | 8270 (21.7) | 11 178 (36.8) | 7649 (28.1) | 18 713 (29.5) | 8470 (22.3) |
| Gla‐100 | ‐ | 1749 (45.6) | ‐ | 21 808 (57.3) | 16 287 (53.7) | 7951 (29.2) | 31 527 (49.6) | 19 114 (50.3) |
| Gla‐300 | ‐ | 519 (13.5) | ‐ | 3655 (9.6) | 0 (0) | 5450 (20.0) | 0 (0) | 5383 (14.2) |
| NPH insulin | ‐ | 28 (0.7) | ‐ | 1095 (2.9) | 2311 (7.6) | 657 (2.4) | 10 823 (17.0) | 1553 (4.1) |
| Only fast‐acting insulin (A10AB) a | ‐ | 77 (2.0) | ‐ | 25 (0.1) | 1007 (3.3) | 1313 (4.8) | 68 (0.1) | 50 (0.1) |
| Noninsulin diabetes medication purchases b | ||||||||
| Any A10B; n (%) | 880 (21.9) | 580 (15.1) | 40 326 (85.5) | 33 007 (86.8) | 1694 (5.6) | 2086 (7.7) | 44 458 (70.0) | 29 495 (77.6) |
| Metformin | 750 (18.7) | 423 (11.0) | 30 367 (64.4) | 20 508 (53.9) | 1461 (4.8) | 1467 (5.4) | 38 026 (59.9) | 19 727 (51.9) |
| Sulfonylureas | 68 (1.7) | <5 (0.1) | 9477 (20.1) | 420 (1.1) | 57 (0.2) | 6 (0.1) | 5739 (9.0) | 222 (0.6) |
| Thiazolidinediones | 23 (0.6) | 5 (0.1) | 2325 (4.9) | 448 (1.2) | 30 (0.1) | 24 (0.1) | 1284 (2.0) | 358 (0.9) |
| DPP‐4 inhibitors | 290 (7.2) | 117 (3.0) | 23 083 (49.0) | 14 464 (38.0) | 224 (0.7) | 122 (0.4) | 10 377 (16.3) | 9961 (26.2) |
| GLP‐1 analogues | <5 (0.1) | 23 (0.6) | 1731 (3.7) | 5898 (15.5) | 0 (0) | 110 (0.4) | 0 (0) | 6425 (16.9) |
| SGLT2 inhibitors | 65 (1.6) | 133 (3.5) | 5257 (11.1) | 10 163 (26.7) | 0 (0) | 606 (2.2) | 0 (0) | 8525 (22.4) |
| Other A10B | 160 (4.0) | 79 (2.1) | 11 147 (23.6) | 6290 (16.5) | 172 (0.6) | 144 (0.5) | 6089 (9.6) | 4512 (11.9) |
Note: Data not shown for patients classified as other than T1D or T2D. Values presented as n (percentage in parenthesis). Abbreviations: ATC, Anatomical Therapeutic Chemical; DPP‐4, dipeptidyl peptidase‐4; Gla, glargine; GLP‐1, glucagon‐like peptide‐1; EOS, end of study; SGLT‐2, sodium‐glucose linked transporter‐2; T1D, type 1 diabetes; T2D, type 2 diabetes.
a
Denotes all medications under the A10AB group – note that only medication purchase data 12 months prior to index or EOS date included.
b
Noninsulin diabetes medications reported at A10B(X) ATC‐code level.